Compare · ILMN vs MTAC
ILMN vs MTAC
Side-by-side comparison of Illumina Inc. (ILMN) and MedTech Acquisition Corporation (MTAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and MTAC operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $31.30B.
- ILMN has hit the wire 16 times in the past 4 weeks while MTAC has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for MTAC).
- Company
- Illumina Inc.
- MedTech Acquisition Corporation
- Price
- -
- -
- Market cap
- $31.30B
- -
- 1M return
- -22.73%
- -
- 1Y return
- +72.75%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
MedTech Acquisition Corporation
MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest ILMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Latest MTAC
- Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)
- Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)
- Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)
- Stevens Jennifer was granted 14,752 shares, increasing direct ownership by 82% to 32,783 units (SEC Form 4)
- Devlin Jodi was granted 17,500 shares (SEC Form 4)
- Murphy Sean was granted 34,144 shares, increasing direct ownership by 205% to 50,788 units (SEC Form 4)
- Katz Steven C was granted 34,144 shares, increasing direct ownership by 99% to 68,587 units (SEC Form 4)
- SEC Form 4 filed by Murphy Sean
- SEC Form 4 filed by Marshak Richard
- SEC Form 424B3 filed by MedTech Acquisition Corporation